$ICCM

IceCure Medical Ltd.

IceCure Medical is an Israeli medical device company based in Caesarea that develops and sells cryoablation systems and disposable products for treating tumors and other conditions. Its lead commercial product is the ProSense system with associated CryoProbes; the system has FDA marketing authorization for treating biologically low-risk breast cancer in women aged 70 and above who receive adjuvant endocrine therapy. Its product family also includes IceSense3, XSense and MSense, which has not been commercialized. The systems use liquid nitrogen to freeze and destroy tissue, and are designed for applications including breast, lung, kidney and bone tumors, as well as nerve ablation for pain management. IceCure makes money by selling systems and disposable probes and introducers to distributors or end users, placing systems with end-user commitments to buy a minimum number of probes per month, and providing service and maintenance. Disposable sales are tied to the number of procedures performed.

AlphAI earnings readFirst Half 2026 · AUG 12IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-YearVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
2
0

No SEC Form 4 filings for $ICCM in the last 30 days.

See all $ICCM insider activity →
Med

ICCM Q3'26 Earnings: EPS estimate is (1.16) USD

ICCM (IceCure Medical Ltd.) will release Q3'26 earnings on November 18. Analysts expect revenue of 876.50 thousand USD and an EPS of (1.16) USD. The announcement is scheduled for 7:30 AM ET (12:30 PM UTC).

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

IceCure Medical (ICCM) received a new patent in China for its cryogenic system connector, expanding its global IP portfolio to 42 patents. The patent covers a connector used in its cryogenic technology platform. This follows recent regulatory approval in China for its ProSense® system and associated cryoprobes. The company focuses on minimally-invasive cryoablation technology for tumor removal.

ICCM sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ICCM (IceCure Medical Ltd.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent ICCM coverage spans technology, earnings and financial news.

What's driving ICCM

  • Ahead of the Q3'26 print, traders can position around a likely loss and small revenue base versus expectations.

    tradingview.com · Nov 17, 2026

  • The announcement sets the date for the upcoming earnings release, creating a short‑term focus on the stock but no immediate catalyst.

    prnewswire.com · Nov 11, 2026

  • The patent grant may modestly improve IceCure's competitive positioning in China but does not immediately affect revenue.

    prnewswire.com · Nov 9, 2026

  • The first-in-human treatment suggests progress toward broader clinical adoption and potential revenue growth.

    stocktitan.net · Oct 27, 2026

  • IceCure Medical has enrolled its first two patients in the US for the ChoICE study, evaluating its ProSense cryoablation system for low-risk breast cancer treatment. The trial aims to recruit 400 patients across 30 centers. ProSense is FDA-cleared for treating small, low-risk breast tumors in patients aged 70+ who are ineligible for surgery. The company aims to gather real-world evidence and expand clinical adoption.

    finance.yahoo.com · Oct 21, 2026

AlphAI scores every news story that mentions ICCM with an AI model for sentiment and relevance, and aggregates insider trades from IceCure Medical Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ICCM

Score

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

IceCure Medical (ICCM) received a new patent in China for its cryogenic system connector, expanding its global IP portfolio to 42 patents. The patent covers a connector used in its cryogenic technology platform. This follows recent regulatory approval in China for its ProSense® system and associated cryoprobes. The company focuses on minimally-invasive cryoablation technology for tumor removal.

$ICCMMedAI 8/10

A breast cancer study treats its first patient by freezing a tumor

IceCure Medical (ICCM) treated the first patient in its ChoICE Study at West Cancer Center, using its ProSense® cryoablation system for breast cancer. The study aims to enroll 400 patients across 30 U.S. sites, generating real-world data. ProSense® is FDA-cleared for specific breast cancer treatments. IceCure develops cryoablation therapy systems for tumor destruction.

IceCure enrols initial patients for ProSense cryoablation trial in US

IceCure Medical has enrolled its first two patients in the US for the ChoICE study, evaluating its ProSense cryoablation system for low-risk breast cancer treatment. The trial aims to recruit 400 patients across 30 centers. ProSense is FDA-cleared for treating small, low-risk breast tumors in patients aged 70+ who are ineligible for surgery. The company aims to gather real-world evidence and expand clinical adoption.

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

IceCure Medical (ICCM) added Legacy Health in Portland, OR, as a new U.S. clinical site for its ChoICE Study, evaluating ProSense® cryoablation for low-risk breast cancer. The study, approved by the FDA, aims to enroll 400 patients across 30 sites. Dr. Nathalie Johnson will lead the site's participation. IceCure's ProSense® is the only FDA-cleared device for this treatment in specific patients.

ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

IceCure Medical Ltd. (ICCM) shares surged over 200% on Wednesday due to increased adoption of its ProSense system for breast cancer treatment. The company reported a 70% increase in U.S. commercial installations since FDA approval in October 2025. CEO Eyal Shamir cited growing physician interest and clinical acceptance. The stock is on track for its best day since August 2021. All three analysts covering ICCM rate it 'Buy' or higher, with an average price target of $44.50, implying a potential u

$ICCMHighAI 8/10

IceCure Medical Wins Regulatory Approval To Market ProSense In China

IceCure Medical (ICCM) received regulatory approval from China's NMPA for its ProSense cryoablation system, expanding its global market. The device, already cleared in the U.S. and Europe, is used to treat tumors in breast, kidney, bone, and lung. The approval was supported by clinical data, and the company plans to accelerate commercialization in China. ICCM's stock is up 1.42% to $2.14.

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

IceCure Medical (ICCM) signed an exclusive distribution agreement with Scovas Medical for ProSense® cryoablation systems in the Netherlands. The deal aims to expand ProSense® commercialization in a market with growing interest in minimally invasive cancer treatments. The THERMAC trial, in Phase III, supports cryoablation's potential for early-stage breast cancer treatment, with a 94% success rate.

Related tickers